← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Obvia Pharmaceuticals, Ltd.
$2,281,385
Total funding
3
Grants
Funding over time
peak $1.3M · FY2022–25$2M$1.5M$1M$500K$0
'22
'23
'24
'25
Funding mix
By agency
DOD$2,281,385 · 3
By mechanism
—$2,281,385 · 3
Investigators at Obvia Pharmaceuticals, Ltd.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
PROGRESSING PRC 210 TO CLINICAL TREATMENT FOR THE PREVENTION OF NEURODEGENERATIVE DISEASES AFTER RADIATION$1,081,762
· FY2025 · Defense Health Agency
NOVEL APPLICATION OF PRC-210 AMINOTHIOL FREE-RADICAL SCAVENGER FOR THE PROTECTION OF VASCULARIZED ALLOTRANSPLANTS$1,000,000
· FY2022 · Defense Health Agency
INCREASING IMMUNE TOLERANCE IN VCAS WITH INNOVATIVE PRC-210 AND IDENTIFYING NEW CORRESPONDING PERIPHERAL BIOMARKER FOR ACUTE AND CHRONIC VCA REJECTION$199,623
· FY2025 · Defense Health Agency